| Viernes
/ Friday 23 |
| 08:30
– 08:50 |
Recogida
de Acreditaciones / Registration |
| 08:50 |
Opening and welcome addresses:
Why this symposium. |
| 09:00 |
Keynote Address
Moderador/Chairperson: Juan José López-Ibor
Servicio de Psiquiatría. Hospital Clínico
San Carlos, Madrid, Es. |
| |
Arvid Carlsson
Department of Pharmacology. University of Göteborg, Sw. |
|
The Dopamine System: Still an important
target for Drug Discovery / El Sistema Dopamínico:
aun una diana importante para el descubrimiento de fármacos.
Following the proposal by Carlsson and Lindqvist in 1963 that
major neuroleptics act by blocking dopamine (and noradrenaline)
receptors, the dopamine system has been a target in attempts
to discover novel antipsychotics with improved balance between
efficacy and side effects. The present paper will deal with
the most recent group of agents acting on this target, i.e.
the dopamine system stabilizers; they seem to offer significant
advantages compared to current antipsychotics. |
| SESION 1
|
Parkinson's disease
Moderador/Chairperson: Juan Carlos Gómez
Director Médico. Lilly S.A., Madrid, Es. |
| 09:40 |
Peter Jenner
Neurodegenerative Diseases Research Centre. GKT School of Biomedical
Sciences, King’s College, London, UK. |
|
Molecular mechanisms in Parkinson’s
disease / Mecanismos moleculares de la enfermedad de Parkinson.
Neuronal cell death in Parkinson’s disease may be associated
with a failure of proteaolysis linked to alterations in the
function of the ubiquitin-proteasome system. Inhibition of proteasomal
function leads to dopaminergic cell death both in vitro and
in vivo. Inflammatory changes also occur in the substantia nigra
in PD as a result of reactive gliosis. Glial cell activation
using LPS leads to destruction of dopaminergic neurones suggesting
that inflammation may contribute to disease progression. |
| 10:10 |
José López Barneo
Departamento de Fisiología. Hospital Universitario Virgen
del Rocío, Sevilla, Es. |
|
Dopamine and GDNF-producing cells in the carotid body:
their use for autotransplantation in Parkinson’s disease
/ Células productoras de dopamina y GDNF en el cuerpo
carotídeo: su utilización para autotransplante
en la enfermedad de Parkinson.
Several dopamine-producing cells have been used for the last
few years in transplantation studies designed to treat Parkinson's
disease, both in human and in animal models of Parkinson's disease.
We have developed a technique based in the intrastriatal autotransplantation
of cells of the carotid body that secrete dopamine and glial
cell line-derived neurotrophic factor (GDNF). We will present
the status of our current research. We will also discuss the
advantages, limitations and future perspectives of this new
methodology for treatment of Parkinson's disease. |
| 10:40 |
Café/Coffee |
| 11:10 |
José Obeso
Unidad de Trastornos del Movimiento y Ganglios Basales. Univ.
de Navarra, Pamplona, Es. |
|
Pathophysiology of the basal ganglia:
therapeutic consequences for Parkinson’s disease / Patofisiología
de los ganglios basales: consecuencias terapéuticas para
la enfermedad de Parkinson.
The severity of dopamine depletion and the associated
pathophysiologic abnormalities in the basal ganglia circuits
determine the severity of parkinsonian signs. Cell replacement
therapy has spurred considerable enthusiasm, most recently for
the use of embryonic stem cells. However, Parkinson’s
disease is a multi-systems degeneration; many symptoms fail
to respond to current treatment and will likely be resistant
even to the most "successful" dopamine cellular replacement
therapy. |
| 11:40 |
Eduardo Tolosa
Servicio de Neurología. Hospital Clínic, Barcelona,
Es. |
|
Emerging strategies in the treatment of Parkinson
disease / Nuevas estrategias en el tratamiento de la Enfermedad
de Parkinson.
In recent years new treatments have become available that have
greatly improved both motor and non-motor complication of Parkinson
disease. These include new atypical antipsychotics and the anticholinesterase
inhibitors and stimulants such as modafinil. Newer treatments
are furthermore emerging which are likely to be effective in
both the symptomatic and neuroprotective treatment of Parkinson
disease, such as some trophic factors, anti-adenosine A2 receptor
drugs or those with antiglutamatergic properties. These new
available treatments and the new, emerging, strategies will
be reviewed. |
| 12:10 |
Discusión 1:
Parkinson's disease |
| 12:45 |
|
| 13:45 |
Almuerzo |
| SESION
2 |
Schizophrenia: a neurodegenerative
disorder?
Moderador/Chairperson: Enrique Baca
Servicio de Psiquiatría. Clínica Puerta de Hierro,
Madrid, Es.
|
| 15:15 |
Robin M Murray
Department of Psychiatry. Institute of Psychiatry, King’s
College, London, UK.
|
|
Schizophrenia: Between development and
degeneration / Esquizofrenia: entre el desarrollo y la degeneración.
Although the neurodevelopmental model was the
predominant model of schizophrenia throughout the 1990s’s,
it is clear that it cannot explain all characteristics of schizophrenia.
The question is whether the decline that occurs in a proportion
of patients is simply a consequence of the psychological and
social disruption caused by psychosis or whether this is the
result of progression of brain structural and neuropsychological
abnormalities. |
| 15:45 |
Tim Crow
Prince of Wales International Centre for Research into Schizophrenia
and Depression. Oxford, UK. |
|
An evolutionary perspective on schizophrenia
/ Una perspectiva evolutiva sobre la esquizofrenia.
Schizophrenic illnesses occur in all populations
whit similar features. Some balancing advantage to the biological
disadvantage associated with the generic predisposition is required.
This, it is suggested, is the human capacity for language, and
that the relevant genetic variation goes back to the origin
of the species at some point in E. Africa 100-150.000 years
ago. |
| 16:15 |
Maria Carlsson
Sahlgrenska Academy (Medical School), Institute of Clinical
Neuroscience. Univ. of Göteborg, Sw. |
|
The role of glutamate in schizophrenia
/ Papel del glutamato en la esquizofrenia.
Cognitive and negative symptoms of schizophrenia
constitute the major therapeutic challenges in this disorder.
This presentation will discuss recent findings from our rodent
hypoglutamatergic models for cognitive and negative symptoms
of schizophrenia. The effects of traditional neuroleptics, a
newer generation antipsychotics, as well as those of so called
dopamine stabilizers will be presented. |
| 16:45 |
Gary D Tollefson
Lilly Research Laboratories. Indianapolis, USA. |
|
Neuroprotection and cognitive enhancement.
The future of the treatment of schizophrenia / Neuroprotección
y mejora cognitiva. Futuro del tratamiento de la esquizofrenia.
While undoubtedly schizophrenia has a neurodevelopmental
aspect, both studies of associated clinical and structural brain
pathomorphology suggest a progressive course. The loss of cortical
gray volume and ventricular enlargement represents a new treatment
target. Data suggesting a neuroplasticity benefit with the atypical
olanzapine will be shared.
|
| 17:15 |
Discusión 2: Schizophrenia:
a neurodegenerative disorder? |
| 17:45 |
Café
/ Coffee |
| 18:15 |
|
| Sábado
/ Saturday 24 |
| SESSION
3 |
Alzheimer's disease
Moderador/Chairperson: Justo García de Yébenes
Servicio de Neurología. Fundación Jiménez
Díaz, Madrid, Es.
|
| 09:00 |
Ezio Giacobini
University Hospitals of Geneva, Department of Geriatrics. University
of Geneva, Ch. |
|
Early diagnosis and treatment of Alzheimer’s
disease: present and future / Diagnóstico temprano
de la enfermedad de Alzheimer: presente y futuro.
Various forms of pharmacological treatment are
being tested clinically in an effort to slow down or block the
conversion of Mild Cognitive Impairment to Alzheimer’s
Disease. Experimental and clinical data suggest that cholinesterase
inhibitors (ChEI), in addition to symptomatic benefit, might
have a delaying effect on Alzheimer’s Disease progress
(Giacobini, 2000). Other approaches being investigated include
anti-inflammatories (rofecoxib), 1200 pats, 3yrs; anti-oxidants
(vit E) + ChEI (donepezil), 769 pats, 3 yrs; nootropics (piracetam),
675 pats, 1yr; AMPA receptor agonists (ampakine), 160 pats,
4 wk. Besides, data from the recent vaccination study (Nitsch
et al, 2003; Hock et al, 2003), with pre-aggregated A-beta-42,
show that patients who generated amyloid plaque immunoreactivity
over one year period, had significantly slower rate of decline
of cognitive functions and improvement in activities of daily
living. These preliminary results suggest that targeting A-beta
with immunization could be of benefit to early cases of Alzheimer’s
Disease. |
| 09:30 |
Jesús Ávila
Centro de Biología Molecular "Severo Ochoa".
CSIC, Es.
|
|
Tau proteins and tauopathies / Proteínas
Tau y taupatías.
The role of tau protein in pathological disorders like Alzheimer’s
disease, and other pathologies, has two main characteristics:
the phosphorylation of the protein, and its aberrant polymerization.
The mechanisms for these two features will be indicated. |
| 10:00 |
Café
/ Coffee |
10:30
|
Peter Davies
Department of Pathology. Albert Einstein College of Medicine,
New York, USA. |
|
Tau pathology and tangles in Alzheimer's
disease as a target for pharmacotherapy / Patología
de Tau y redes como diana farmacoterapéutica en la enfermedad
de Alzheimer.
Abnormalities in tau in Alzheimer’s disease include conformational
changes as well as hyperphosphorylation. These alterations are
exquistively sensitive indicators of neuronal damage in this
disease. There is now also evidence that tau abnormalities are
responsible for the death of neurons, and the mechanisms involved
are very obvious targets for new therapeutics. |
| 11:00 |
Steven Paul
Executive Vice President, Science and Technology. Lilly Research
Laboratories. Indianapolis, USA.
|
|
Alzheimer's disease: Genetic and pharmacological
evidence supporting the amyloid cascade hypothesis / Evidencia
genética y farmacológica en soporte de la hipótesis
de cascada de amiloide.
Revolutionary advances in our understanding of
the genetic and consequent cellular/biochemical etiologies of
a group of phenotypically similar neurodegenerative disorders,
referred to as Alzheimer’s Disease (AD), have heralded
a new era in potential therapeutic intervention. I will review
these findings, including recent data from our laboratory delineating
an important role for apoE in the process of amyloidogenesis
in vivo, and present several ongoing approaches to drug discovery
made possible by this new information. Similar approaches to
other neuropsychiatric disorders will undoubtedly prove feasible
once the genetic underpinnings of their etiologies are delineated. |
| 11:30 |
Discusión
3: Alzheimer's disease |
| 12:00 |
|
| 13:00 |
Conferencia Clausura
Moderador / Chairperson: Francisco Mora
Catedrático de Fisiología. Facultad de Medicina,
UCM. Madrid, Es. |
|
Francesc Artigas
Profesor Investigación CSIC, IIBB. Presidente, Sociedad
Española de Neurociencias. |
|
The role of prefrontal cortex in mental
health and disease / Papel del cortex prefrontal en la salud
y la enfermedad mentalesl.
The prefrontal cortex (PFC) is involved in many
higher brain functions which are altered in severe psychiatric
disorders. PFC pyramidal neurons express the receptors for which
antipsychotic drugs show high affinity. The current evidence
supporting a major role of these neurons in the pathophysiology
and treatment of schizophrenia, and possibly major depression,
will be reviewed. |
| 13:40 |
Despedida
Juan José López-Ibor
Francisco Mora Teruel
José Antonio Gutiérrez Fuentes
Juan Carlos Gómez Pérez |
| |
| (*)SEMINARIOS |
| |
SEMINARIO 1 |
| |
Ponente: Gurutz Linazasoro
Centro de Neurología y Neurocirugía Funcional,
Clínica Quirón, San Sebastián, Guipúzcoa.
|
|
Diagnosis and treatment of Parkinson’s
disease / Diagnóstico y tratamiento de la enfermedad
de Parkinson.
Since no biological markers of the disease are available, the
diagnosis of PD is still based on clinical grounds. Clues to
establish a diagnosis will be explained as well as recent advances
in complementary tests. Current management of early and late
PD will be reviewed emphasizing the role of recent therapies
and the potential of emerging therapies. |
| SEMINARIO
2 |
|
Ponente: Enrique Álvarez
Jefe del Servicio de Psiquiatría del Hospital de Sant
Pau de Barcelona.
|
|
Diagnosis and treatment of Schizophrenia
/ Diagnóstico y tratamiento de la Esquizofrenia.
La era de la Medicina Científica debe estar
presente también en la Psiquiatría. Los clínicos
apoyaran sus decisiones en pruebas científicas de su
utilidad. Por otra parte la era de la terapéutica de
caja negra ha terminado y los Psiquiatras emplearan fármacos
de los que conocerán su intimo mecanismo de acción.
|
| SEMINARIO
3 |
| |
Ponente: Manuel Martínez Lage
Profesor y Consultor de Neurología, U Trastornos de Memoria,
Clínica Universitaria de Navarra, Pamplona. |
|
Diagnosis and treatment of Alzheimer’s
disease / Diagnóstico y tratamiento de la enfermedad
de Alzheimer.
Early detection of Alzheimer’s disease.
Clinical, biological, and imaging markers.
AchE inhibitors: donepezil and rivastigmine.
Nicotinic AchER modulators: galantamine.
Memantine.
Treatment of behavioral and psychological symptoms.
Antiamyloid therapies. Facts and hopes.
Cognitive psychostimulation.
|
| Viernes
23 |
Sábado
24 |
| 12:45
|
18:15
|
12:00 |
| SEM- 1 |
SEMI-2 |
SEM- 1 |
SEM- 3 |
SEM- 2 |
SEM- 3 |
|
| Seminarios:
dirigidos a la discusión y orientación de los
aspectos prácticos relacionados con la prevención,
el diagnóstico y el tratamiento. |
